The economic impact of galantamine vs placebo: An analysis based on functional capacity in a Swedish cohort study

Figures & data

Table 1.  Unit costs.

Resource item	Unit cost (SEK^a)
Informal care	91/hour
Home care^b	350/hour
Institutional care^c	1185/day
Hospital care	3000/day

^aDivide by 10 to obtain approximate costs in €.

^bTotal costs includes all salary costs (wage, pension, holiday) and transportation during work.

^c‘Hotel costs’ (for accommodation and food) are excluded.

Table 2.  Distribution in dependency in ADL (Katz’ items) (percentages) in the KNP and the Swedish sub-sample of GAL-INT-1 (the latter after transformation from DAD).

ADL lost	All patients in KNP with dementia	Patients in KNP withdementia living at home	GAL-INT-1
0	41.2	73.1	58.0
1–2	17.6	16.4	32.5
3–4	15.8	6.0	8.0
5–6	25.5	4.5	1.5
Total	100	100	100

Table 3.  Annual costs (SEK)* of dementia in the KNP, based on regression analysis of number of ADL abilities lost.

ADL lost	All patients in KNP with dementia	Patients in KNP with dementia living at home
0	221,906	110,649
1–2	305,589	192,064
3–4	389,272	273,479
5–6	472,955	354,894

*Divide by 10 to obtain approximate costs in €.

Table 4.  Annual costs of dementia (SEK*) based on stage-specific costs according to number of ADL abilities lost and data from the KNP.

ADL lost	Direct medical costs	Direct non-medical costs	Informal care	Total costs (SD)
All patients
0	12,944	151,078	36,405	200,426 (184,101)
1–2	13,623	331,091	24,727	369,441 (133,816)
3–4	15,823	378,705	30,660	425,188 (76,135)
5–6	9,408	408,221	26,126	443,756 (56,844)
0–6	12,617	282,700	30,935	326,252 (175,487)
Patients living at home
0	13,446	43,728	48,487	105,660 (120,009)
1–2	27,218	162,571	33,547	223,336 (105,389)
3–4	18,293	116,070	166,075	300,438 (145,342)
5–6	21,460	141,863	132,860	296,183 (14,036)
0–6	16,355	70,415	57,185	143,955 (133,438)

* Divide by 10 to obtain approximate costs in €.

Table 5.  Six-month costs per patient with AD with and without galantamine, based on the regression analysis model.

	n	Costs (SEK)*	95% CI
Living at home
Galantamine	48	79,774	51,605–107,943
Placebo	32	110,809	76,310–145,309
All patients
Galantamine	48	135,930	108,277–163,582
Placebo	32	166,111	132,243–199,978

* Divide by 10 to obtain approximate costs in €.

Table 6.  Six-month costs per patient with AD with and without galantamine, based on the stage-based costing model.

	n	Costs (SEK)*	95% CI
Living at home
Galantamine	48	129,273	114,747–143,799
Placebo	32	129,381	111,591–147,172
All patients
Galantamine	48	185,387	168,248–203,427
Placebo	32	185,525	164,983–208,068

*Divide by 10 to obtain approximate costs in €.

Figure 1.  Health economic decision matrix. T, new treatment; C, comparator (current standard of care, placebo, no treatment, etc.).